01Core principlesThe concepts and mechanisms needed to understand the subject.
A focal lesion discovered on a single portal-venous CT is often incompletely characterised. The reader should describe organ of origin, size, margins, attenuation or signal, calcification, fat, enhancement, duct or collecting-system relation, vascular involvement and comparison. A recommendation should name the modality and question rather than simply say follow-up.
Liver assessment changes with background risk. A classic benign pattern in a healthy liver may need no further action, while cirrhosis or known malignancy raises pre-test probability and invokes disease-specific multiphasic criteria. MRI offers tissue and hepatobiliary contrast; multiphasic CT is fast and stages suspected malignancy. Biopsy is considered only after imaging and MDT review because vascular lesions, sampling error and tract consequences matter.
Pancreatic lesions include solid masses, inflammatory collections and cystic neoplasms. Pancreatic-protocol CT assesses enhancement, vessels and metastases; MRI-MRCP depicts duct communication and internal cyst features; EUS can inspect mural nodules and obtain tissue selectively. Renal characterisation focuses on true enhancement, cyst complexity, macroscopic fat and extension.
Key points
- Characterisation asks whether a lesion contains fat, fluid, blood or enhancing tissue and how it behaves across phases; size alone rarely answers this.
- First identify organ, patient cancer and liver-risk context, symptoms, prior imaging and whether the study was adequately protocoled.
- Use contrast-enhanced MRI preferentially when a benign liver lesion is suspected, while CT provides rapid assessment when malignancy or complications are concerns.
- For possible adult RCC, NICE NG256 recommends multiphasic contrast-enhanced abdominal CT, or MRI when CT is unsuitable.
- For pancreatic cysts, use pancreatic-protocol CT or MRI-MRCP; consider EUS when malignancy likelihood or need for surgery remains unclear.
- Do not invent a universal follow-up interval: organ, lesion class, size, growth, patient risk and definitive guideline determine action.
02Mechanisms and patternsImportant relationships and how to distinguish them.
An increase in lesion attenuation or signal after contrast indicates vascularised tissue; compare matched phases and account for pseudoenhancement.
Thin wall, homogeneous fluid signal, no septum, nodule or enhancement supports a benign simple cyst in the appropriate organ.
Cirrhosis, known malignancy, hereditary syndrome, pancreatitis history or visible haematuria changes prior probability and the correct algorithm.
Solid component, mural nodule, main-duct change, obstructive jaundice or upstream atrophy raises concern for malignant or pre-malignant disease.
Renal sinus or perinephric extension, renal-vein thrombus, nodes and distant disease affect staging and treatment planning.
Rupture, haemorrhage, infection, duct obstruction or organ dysfunction requires acute assessment separate from long-term neoplastic risk.
03Interpreting evidenceInformation, measurements and their limitations.
Consider the information, its meaning and its limitations before deciding what follows.
- 01
Multiphasic liver CT or MRI - Why
- Assess arterial, portal and delayed enhancement and background liver.
- Interpretation and limitations
- A characteristic pattern may establish diagnosis; indeterminate lesions in high-risk liver require specialist pathways rather than generic follow-up.
- 02
Pancreatic-protocol CT - Why
- Assess solid pancreatic masses, vessels, nodes and metastatic disease.
- Interpretation and limitations
- A routine single-phase CT may miss subtle hypoenhancing tumour or vascular detail and should not be called definitive.
- 03
MRI with MRCP - Why
- Characterise pancreatic cyst contents and duct communication without ionising radiation.
- Interpretation and limitations
- Use morphology and duct relation to guide surveillance, EUS or surgery; motion and device constraints can limit quality.
- 04
Multiphasic renal CECT - Why
- Determine enhancement, cyst complexity, local extension, renal vein and nodes.
- Interpretation and limitations
- NICE NG256 recommends it for possible RCC; use MRI when CT is unsuitable.
- 05
Endoscopic ultrasound - Why
- Resolve pancreatic lesion morphology and obtain selected tissue when results change management.
- Interpretation and limitations
- Sampling can be nondiagnostic and should follow dedicated imaging and specialist discussion.
- 06
Prior imaging comparison - Why
- Establish growth, stability and whether a new lesion is truly new.
- Interpretation and limitations
- Compare like modality and phase; apparent size change may reflect slice thickness, enhancement or measurement plane.
04Applied reasoningWorked examples connecting principles to decisions.
01Worked caseIndeterminate portal-venous lesionA routine CT identifies an unexpected focal lesion that lacks a definitive benign pattern.+
- 1Context: establish organ, symptoms, liver disease, cancer history, renal function, pancreatitis and hereditary risk.
- 2Reasoning: inspect whether fluid, fat, blood or enhancement is present and whether the original phase can answer the organ-specific question.
- 3Outcome: choose dedicated liver MRI, pancreatic CT or MRI-MRCP, or multiphasic renal CT or MRI and route to the relevant MDT if suspicious.
- 4Verification: compare prior images, document the final classification and ensure any surveillance or intervention has a named owner.
02Organ-specific routeComplete characterisationA liver, pancreatic or renal lesion remains indeterminate after initial imaging.+
- 1For liver, separate healthy from high-risk background and use multiphasic contrast imaging, often MRI for suspected benign disease.
- 2For pancreas, distinguish solid from cystic and use pancreatic CT or MRI-MRCP before selective EUS.
- 3For kidney, demonstrate enhancement and cyst complexity with multiphasic CT or MRI and assess veins, nodes and metastases.
- 4Discuss indeterminate or high-risk findings in the organ-specific MDT before biopsy, surveillance or treatment.
03Complication routeAddress acute harmThe lesion is associated with haemorrhage, obstruction, sepsis, pancreatitis or organ dysfunction.+
- 1Resuscitate and identify whether arterial bleeding, duct obstruction, infected collection or urinary obstruction is present.
- 2Select angiographic, portal-venous, delayed, MRCP or ultrasound information according to the complication.
- 3Involve interventional radiology, endoscopy or surgery early for source control or decompression.
- 4Return to neoplastic characterisation only after immediate safety and physiology are addressed.
05Checking understandingVerify the reasoning, revisit uncertainties and apply feedback.
- Record the definitive imaging classification and the evidence supporting benignity or concern.
- Use consistent modality and measurement plane when growth drives a decision.
- Track surveillance recommendations to completion and assign ownership across primary care and specialist teams.
- Monitor renal function when repeated contrast imaging or nephron loss is relevant.
- Reassess promptly for jaundice, haematuria, severe pain, fever or haemodynamic deterioration.
06Special situationsVariants, exceptions and circumstances that change the usual approach.
Incidental is not benign
Incidental describes how a lesion was found; morphology, patient risk and interval behavior determine its significance.
Phase creates appearance
A lesion can be inconspicuous or mimic another diagnosis if arterial, portal or delayed enhancement is not compared appropriately.
Fat needs classification
Macroscopic fat can support specific benign lesions, while microscopic fat and mixed tissue require organ-specific interpretation.
Bosniak is cystic
Bosniak classification applies to cystic renal masses after adequate enhancement assessment and should not be used for every solid lesion.
Biopsy has a question
Sampling is useful when histology changes management; it can be nondiagnostic and should not precede adequate imaging by reflex.
Surveillance is individualised
A follow-up interval should cite the applicable lesion pathway and account for age, comorbidity, growth and treatment candidacy.
07Common pitfallsFrequent interpretation and management errors.
- 01
Calling a lesion benign from size alone.
- 02
Applying a low-risk incidental algorithm to cirrhosis or known cancer.
- 03
Characterising enhancement from unmatched phases or inadequate technique.
- 04
Using one generic follow-up interval for liver, pancreatic and renal lesions.
- 05
Biopsying before organ-specific imaging and MDT review have defined the question.